SAB Biotherapeutics, Inc. (SABS)
3.99
+0.04
(+1.01%)
USD |
NASDAQ |
Dec 19, 16:00
3.96
-0.03
(-0.75%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 189.95M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 2.31% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 919.50 |
| Price to Book Value | 1.151 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0375 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL. |
| URL | http://www.sab.bio |
| Investor Relations URL | https://ir.sabbiotherapeutics.com/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 27, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL. |
| URL | http://www.sab.bio |
| Investor Relations URL | https://ir.sabbiotherapeutics.com/ |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 27, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |